Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Anti-cancer vaccine around the corner

​Researchers in the group of Prof. Dr. Peter Vandenabeele (VIB/UGent) show that killed tumour cells can serve as a potent vaccine that stimulates …


Preventing cervical cancer: vaccinating or freezing?

The group of human papillomaviruses has over 100 types, of which at least thirteen can cause cancer. The virus is present in people all over the w…


Vaccinating against cancer with dendritic cells

Founded as a spin-off from the French Blood Bank, PDC*line Pharma is focused on developing immunotherapeutic vaccines. These vaccines contain thei…

POPULAR TAGS

Genticel focuses on curing HPV before it turns into cervical cancer

Written by GK on in the category news with the tags , .


70% of cervical cancer cases are caused by human papillomavirus (HPV) and the traditional HPV vaccines are only useful to prevent, not to treat the infection. Genticel (GTCL) is developing a solution for those who had been previously infected with HPV, and for whom the vaccine would no longer be active, including most adult women carrying the cancerogenic HPV-virus. The company is developing innovative immunotherapies that will work by avoiding cancers that are caused by HPV. They are focusing specifically on preventing cervical cancer by eliminating HPV infection. ProCervix, a therapeutic vaccine currently in the Phase 2 of clinical trials, aims at treating the infection before it turns into cancer. This is a first-in-class immunotherapeutic candidate and a potential blockbuster that could reach about 1 billion euro sales.

The French biotech company Genticel, founded by the Belgian Benedikt Timmerman - former senior director R&D of Novartis Seeds is currently expanding beyond Europe. To obtain licensing revenue from other applications and to increase the visibility for their technology platform on the international market, Genticel has signed a partnership

Read more about: , .

RELATED ARTICLES
Anti-cancer vaccine around the corner

​Researchers in the group of Prof. Dr. Peter Vandenabeele (VIB/UGent) show that killed tumour cells can serve as a potent vaccine that stimulates …


Preventing cervical cancer: vaccinating or freezing?

The group of human papillomaviruses has over 100 types, of which at least thirteen can cause cancer. The virus is present in people all over the w…


Vaccinating against cancer with dendritic cells

Founded as a spin-off from the French Blood Bank, PDC*line Pharma is focused on developing immunotherapeutic vaccines. These vaccines contain thei…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Janssen UGent XpandInnovation KU Leuven Biowin Flanders.bio Itera Life Science GSK V-Bio Ventures Turnstone

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.